Approved Treatments for COVID-19

Name
Approved Treatments for COVID-19
Accession Number
DBCAT005187
Description

Treatments that have been approved for the indication of treating COVID-19 infections

Drugs
DrugDrug Description
RemdesivirA nucleoside analog used to treat RNA virus infections including COVID-19.
RegdanvimabA monoclonal antibody targeted against the SARS-CoV-2 spike protein used to treat patients with COVID-19 who are at risk of progressing to severe COVID-19.
CasirivimabPart of an investigational recombinant monoclonal antibody cocktail used to treat mild to moderate COVID-19.
ImdevimabPart of an investigational recombinant monoclonal antibody cocktail used to treat mild to moderate COVID-19.
BebtelovimabA human IgG1κ monoclonal antibody targeted against the spike protein of SARS-CoV-2 which is used in the treatment of mild-to-moderate COVID-19.
SotrovimabA monoclonal antibody for the treatment of mild-to-moderate COVID-19 in patients at increased risk for death or hospitalization.
Drugs & Drug Targets
DrugTargetType
RemdesivirReplicase polyprotein 1abtarget
RemdesivirRNA-directed RNA polymerase Ltarget
RemdesivirCytochrome P450 2C8enzyme
RemdesivirCytochrome P450 2D6enzyme
RemdesivirCytochrome P450 3A4enzyme
RemdesivirSolute carrier organic anion transporter family member 1B1transporter
RemdesivirP-glycoprotein 1transporter
RemdesivirSolute carrier organic anion transporter family member 1B3transporter
RemdesivirBile salt export pumptransporter
RemdesivirMultidrug resistance-associated protein 4transporter
RemdesivirSodium/bile acid cotransportertransporter
RemdesivirLiver carboxylesterase 1enzyme
RemdesivirLysosomal protective proteinenzyme
RemdesivirReplicase polyprotein 1abtarget
RemdesivirReplicase polyprotein 1abtarget
RemdesivirMultidrug and toxin extrusion protein 1transporter
RegdanvimabSpike glycoproteintarget
CasirivimabSpike glycoproteintarget
ImdevimabSpike glycoproteintarget
BebtelovimabSpike glycoproteintarget
SotrovimabSpike glycoproteintarget